Cystic Fibrosis Related Diabetes Meeting

Event Details

Meeting Objectives

Advancements in the management of patients with Cystic Fibrosis have substantially extended their life expectancy. As CF patients age, there is an increased incidence of diabetes mellitus. This form of diabetes has features of both type 1 and type 2 diabetes and is called Cystic Fibrosis Related Diabetes or CFRD. CFRD occurs in 35% of young adults ages 20 to 29 and 43% of adults over 30 years of age. In addition, many CF patients with CFRD experience weight loss and have a steeper decline in lung function. In contrast to other types of diabetes, CFRD presents unique diagnostic and therapeutic challenges that necessitate more rigorous answers. The goal of this workshop is to better understand the causes and consequences of CFRD as well as discuss emerging strategies to better control this metabolic complication. During the two panel discussions, participants will identify gaps and develop research questions that need to be addressed to more fully understand the causes, consequences, and management of CFRD.

Agenda

May 25, 2011

8:30 a.m. - 8:45 a.m.

Welcome
Gregory G. Germino, Deputy Director, NIDDK

8:45 a.m. - 9:30 a.m.

Keynote:
CFRD: Overview of Our Current Understanding, and Where Do We Go From Here?
Toni Moran, M.D., University of Minnesota

Session 1: Causes and Consequences

Chair: Larry Phillips, M.D., Emory University

9:30 a.m. - 10:00 a.m.

Insulin Secretion and Cystic Fibrosis (CF)
Remi Rabasa-Lhoret, M.D., University of Montreal

10:00 a.m. - 10:30 a.m.

Islet Amyloid in Cystic Fibrosis: Blood or Bullet?
Peter Butler, M.D., University of California at Los Angeles

10:30 a.m. - 10:45 a.m.

Break

10:45 a.m. - 11:15 a.m.

Hypoxia and Glucose Tolerance
Andrea Kelly, M.D., The Children's Hospital of Philadelphia

11:15 a.m. - 11:45 a.m.

Inflammation and Lung Disease in Cystic Fibrosis Related Diabetes
James Chmiel, M.D., Case Western Reserve University School of Medicine

11:45 a.m. - 12:15 p.m.

The Role of Redox Imbalance and Oxidative Stress in the Development of CFRD
Arlene Stecenko, M.D., Emory University

12:15 p.m. - 12:45 p.m.

Exocrine Pancreatic Disease in CF and Risk of CFRD
Steven Freedman, M.D., Ph.D., Deaconess Hospital

12:45 p.m. - 1:45 p.m.

Lunch

1:45 p.m. - 2:15 p.m.

A Structural Perspective of CFTR Function and Dysfunction
Philip Thomas, Ph.D., University of Texas Southwestern Medical Center

2:15 p.m. - 2:45 p.m.

Genetic Modifiers of Cystic Fibrosis Related Diabetes
Scott Blackman, M.D., Ph.D., The Johns Hopkins University

2:45 p.m. - 3:15 p.m.

Lung Disease and Early Glycemic Instability in the Cystic Fibrosis Ferret Model
Andrew Norris, M.D., Ph.D., University of Iowa

3:15 p.m. - 3:45 p.m.

Panel Discussion to Identify Research Needs I
Discussion Leaders: Catherine McKeon, Ph.D., NIDDK and Saul Malozowski, M.D., Ph.D., MBA, NIDDK

3:45 p.m. - 4:00 p.m.

Break

Session 2: Clinical Trials and Patient Management

Chair: Toni Moran, M.D., University of Minnesota

4:00 p.m. - 4:30 p.m.

Clinical Care Guidelines for Cystic Fibrosis Related Diabetes
Bonnie Slovis, M.D., Vanderbilt University

4:30 p.m. - 5:00 p.m.

Nationwide Implementation of CFRD Screening and Treatment
Sam Casella, M.D., Dartmouth College

5:00 p.m. - 5:30 p.m.

CFRD: Predicting, Screening, and Monitoring
Larry Phillips, M.D., Emory University

May 26, 2011

8:30 a.m. - 9:00 a.m.

Nutrition and Cystic Fibrosis: Can We Make a Difference?
Daniel Peckham, M.D., University of Leeds, United Kingdom

9:00 a.m. - 9:30 a.m.

Insulin Versus Other Diabetes Agents
Gary Onady, M.D., Wright State University

9:30 a.m. - 10:00 a.m.

Patient Adherence and Cystic Fibrosis Related Diabetes: Much to Learn and Then to Apply
Scott Powers, Ph.D., ABPP, Cincinnati Children's Hospital

10:00 a.m. - 10:30 a.m.

Panel Discussion to Identify Research Needs II
Discussion Leader: John Buse, M.D., Ph.D., University of North Carolina at Chapel Hill

10:30 a.m.

Adjournment